Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $37.43.

Several analysts recently commented on the stock. Chardan Capital raised their price target on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 8th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, March 6th. Raymond James raised their price target on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a research report on Thursday, January 4th. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Piper Sandler increased their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th.

Insider Buying and Selling at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 13,000 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $24.34, for a total value of $316,420.00. Following the transaction, the senior vice president now directly owns 124,228 shares of the company’s stock, valued at $3,023,709.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Richard William Scalzo sold 13,000 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $24.34, for a total value of $316,420.00. Following the transaction, the senior vice president now directly owns 124,228 shares of the company’s stock, valued at $3,023,709.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Wildon Farwell sold 5,493 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $25.07, for a total transaction of $137,709.51. Following the completion of the transaction, the insider now directly owns 163,503 shares in the company, valued at $4,099,020.21. The disclosure for this sale can be found here. Insiders have sold a total of 1,888,532 shares of company stock valued at $44,687,450 over the last ninety days. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Fcpm Iii Services B.V. acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $81,543,000. Frazier Life Sciences Management L.P. acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $15,758,000. Commodore Capital LP acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $11,970,000. Vivo Capital LLC increased its position in Dyne Therapeutics by 58.0% during the first quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock worth $46,422,000 after purchasing an additional 600,000 shares during the last quarter. Finally, Braidwell LP increased its position in Dyne Therapeutics by 32.2% during the third quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after purchasing an additional 444,100 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $25.44 on Wednesday. The firm has a market capitalization of $2.19 billion, a P/E ratio of -6.46 and a beta of 0.95. Dyne Therapeutics has a 1-year low of $6.40 and a 1-year high of $30.27. The company’s fifty day moving average price is $26.05 and its 200-day moving average price is $17.61.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.17). Equities analysts anticipate that Dyne Therapeutics will post -3.25 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.